Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: A retrospective analysis

Haematologica

Volumn 88, Issue 5, 2003, Pages 489-496

  Piga, Antonio ^a   Gaglioti, Carmen ^a   Fogliacco, Eugenia ^a   Tricta, Fernando ^b  

^a UNIVERSITY OF TURIN   (Italy)

^b NONE

Author keywords

Chelation; Deferiprone; Deferoxamine; Iron; Thalassemia

Indexed keywords

DEFERIPRONE; DEFEROXAMINE;

ADOLESCENT; ADULT; ARTICLE; CARDIOTOXICITY; CHELATION THERAPY; COMPARATIVE STUDY; FEMALE; HEART DISEASE; HEART PROTECTION; HUMAN; IRON OVERLOAD; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; RETROSPECTIVE STUDY; SURVIVAL; THALASSEMIA MAJOR;

ADOLESCENT; ADULT; BETA-THALASSEMIA; CHILD; DEFEROXAMINE; DISEASE-FREE SURVIVAL; FEMALE; HEART DISEASES; HUMANS; IRON CHELATING AGENTS; IRON OVERLOAD; MALE; PYRIDONES; RETROSPECTIVE STUDIES;

EID: 0038187626     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Gabutti V, Piga A. Results of Long-Term Iron-Chelating Therapy. Acta Haematol 1996;95:26-36.
2. Wolfe LC, Olivieri NF, Sallan D, Colan S, Rose V, Propper RD, et al. Prevention of cardiac disease by subcutaneous deferoxamine in patients with thalassemia major. N Engl J Med 1985;312:1600-3.
3. Aldouri MA, Wonke B, Hoffbrand AV, Flynn DM, Ward SE, Agnew JE, et al. High incidence of cardiomyopathy in β-thalassaemia patients receiving regular transfusion and iron chelation: reversal by intensified chelation. Acta Haematol 1990;84:113-7.
4. Brittenham GM, Griffith PM, Nienhuis AW, McLaren CE, Young NS, Tucker EE, et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med 1994;331:567-73.
5. Giardina PJV, Ehlers KH, Engle MA, Grady RW, Hilgartner MW. The effect of subcutaneous deferoxamine on the cardiac profile of thalassemia major: a five-year study. Ann N Y Acad Sci 1985;445:282-92.
6. Zurlo MG, De Stefano P, Borgna-Pignatti C, Di Palma A, Piga A, Melevendi C, et al. Survival and causes of death in thalassaemia major. Lancet 1989;2:27-30.
7. Olivieri NF, Nathan DG, MacMillan JH, Wayne AS, Liu P, McGee A, et al. Survival in medically treated patients with homozygous β-thalassemia. N Engl J Med 1994;331:574-8.
8. Borgna-Pignatti C, Rugolotto S, DeStefano P, Piga A, Di Gregorio F, Gamberini MR, et al. Survival and disease complications in thalassemia major. Ann N Y Acad Sci 1998;850:227-31.
9. Telfer PT, Prestcott E, Holden S, Walker M, Hoffbrand AV, Wonke B. Hepatic iron concentration combined with long-term monitoring of serum ferritin to predict complications of iron overload in thalassaemia major. Br J Haematol 2000;110:971-7.
10. Modell B, Khan M, Darlison M. Survival in β-thalassaemia major in the UK: data from the UK Thalassaemia Register. Lancet 2000;355:2051-2.
11. De Franceschi L, Shalev O, Piga A, Collell M, Olivieri O, Corrocher R, et al. Deferiprone therapy in homozygous human β-thalassemia removes erythrocyte membrane free iron and reduces KCl cotransport activity. J Lab Clin Med 1999;133:64-9.
12. Shalev O, Repka T, Goldfarb A, Grinberg L, Abrahamov A, Olivieri NF, et al. Deferiprone (L1) chelates pathologic iron deposits from membranes of intact thalassemic and sickle red blood cells both in vitro and in vivo. Blood 1995;6:2008-13.
13. Link G, Konijn AM, Breuer W, Cabantchik ZI, Hershko C. Exploring the "iron shuttle" hypothesis in chelation therapy: effects of combined deferoxamine and deferiprone treatment in hypertransfused rats with labeled iron stores and in iron-loaded rat heart cells in culture. J Lab Clin Med 2001;138:130-8.
14. Töndury P, Zimmermann A, Nielsen P, Hirt A. Liver iron and fibrosis during long-term treatment with deferiprone in Swiss thalassaemic patients. Br J Haematol 1998;101:413-5.
15. Olivieri NF, Brittenham GM, McLaren CE, Templeton DM, Cameron RG, McClelland RA, et al. Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major. N Engl J Med 1998;339:417-23.
16. Hoffbrand AV, Al-Refaie FN, Davis B, Siritanakatkul N, Jackson BFA, Cochrane J, et al. Long-term trial of deferiprone in 51 transfusion-dependent iron overloaded patients. Blood 1998;91:295-300.
17. Olivieri NF, Butany J, Templeton DM, Brittenham GM. Cardiac failure and myocardial fibrosis in a patient with thalassemia major (TM) treated with long-term deferiprone. Blood 1998;92 Suppl 1.532 [abstract].
18. Cohen AR, Galanello R, Piga A, DiPalma A, Vullo C, Tricta F. Safety profile of the oral iron chelator deferiprone: a multicentre study. Br J Haematol 2000;108:305-12.
19. th International Conference on Oral Chelators in the Treatment of Thalassemia and other Diseases and Biomed Meeting, Limassol, Cyprus. 2000;p3 [abstract].
20. Piga A, Galanello R, Forni GL, Quarta G, Capellini MD, Alberti D, et al. Changing pattern of splenectomy in thalassemia. Blood 2001;98:3682 [abstract].
21. Dolgin M, Editor. Nomenclature and criteria for diagnosis of disease of the heart and great vessels. The criteria committee of the New York heart association. Little, Brown & Co., Boston, Mass. USA. 1994. p. 253-6.
22. Gabutti V, Piga A, Sacchetti L, Sandri A, Biginelli M, Saracco P, et al. Quality of life and life expectancy in thalassemic patients with complications. Prog Clin Biol Res 1989;309:35-41.
23. Piga A, Longo F, Voi V, Facello S, Miniero R, Dresow B. Late effects of bone marrow transplantation for thalassemia. Ann NY Acad Sci 1998;850:312-5.
24. Parkes JG, Hussain RA, Olivieri NF, Templeton D. Effects of iron loading on uptake, speciation, and chelation of iron in cultured myocardial cells. J Lab Clin Med 1993;122:36-47.
25. Olivieri NF, Belluzzo N, Muraca M, MacKenzie CC, Milone S, Polsinelli K, et al. Evidence of reduction in hepatic, cardiac and pituitary iron stores in patients with thalassemia major during long-term therapy with the orally active iron chelating agent L1. Blood 1994;84 Suppl 1:109[abstract].
26. Olivieri NF, Koren G, Matsui D, Liu P, Blendis L, Cameron R, et al. Reduction of tissue iron stores and normalization of serum ferritin during treatment with the oral iron chelator L1 in thalassemia intermedia. Blood 1992;79:2741-8.
27. Olivieri NF, Brittenham GM, Armstrong SA, Basran RK, Daneman R, Daneman N, et al. First prospective randomized trial of the iron chelators deferiprone (L1) and deferoxamine. Blood 1995;86 Suppl 1:249a[abstract].
28. Anderson LJ, Wonke B, Prescott E, Holden S, Walker JM, Pennell DJ. Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in β-thalassaemia. Lancet 2002;360:516-20.
29. Maggio A, D'Amico G, Morabito A, Capra M, Ciaccio C, Cianciulli P, et al. Deferiprone versus deferoxamine in patients with thalassemia major: a randomized clinical trial. Blood Cells Mol Dis 2002;28:196-208.
30. Hershko C, Graham B, Bates BW, Rachmilewitz EA. Nonspecific serum iron in thalassaemia: an abnormal serum iron fraction of potential toxicity. Br J Haematol 1978;40:255-63.
31. Modell B. The clinical approach to thalassaemia. London: Grune & Stratton. 1984.
32. Faller B, Nick H. Kinetics and mechanism of iron (III) removal from citrate by desferrioxamine B and 3-hydroxy-1,2- dimethyl-4-pyridone. J Am Chem Soc 1994;116:3860-5.